Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of NIO752 in progressive supranuclear palsy with open-label extension
NL-OMON61059Phase 3Not yet recruiting
- Sponsor
- Novartis
- Start
- Jun 2026
- Modality
- Vaccine mRNA → mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of NIO752 in progressive supranuclear palsy (PSP), sponsored by Novartis. Primary endpoint: Change from baseline in rPSPRS-10 score at Week 72. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
NIO752
03
Conditions
progressive supranuclear palsy (PSP)
Beyond the preview
Go deeper on NL-OMON61059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61059.